IPCA Laboratories
1,371.90
-17.90(-1.29%)
Market Cap₹35,259.80 Cr
PE Ratio40.24
IndustryHealthcare
Company Performance:
1D-1.29%
1M-3.10%
6M-18.96%
1Y+20.85%
5Y+66.39%
View Company Insightsright
Latest news about IPCA Laboratories
Ipca Labs Receives 'Add' Rating from Dolat Capital Post Q4 Results Jun 01, 2025
Dolat Capital has maintained an 'Add' rating on Ipca Laboratories Limited following its Q4 results. The brokerage firm highlights multiple growth drivers including cost efficiencies, Unichem portfolio scale-up, and US market expansion plans. Ipca Labs aims to launch 12-13 new products in the US over the next two years, signaling a strong commitment to portfolio diversification and market share growth in this key pharmaceutical market.
IPCA Laboratories: Q4 Profit Rises 14%, but Full-Year EBITDA Margin Falls Short of Guidance May 29, 2025
IPCA Laboratories to Sell Tarapur Facility and Acquire Unichem Ireland in Strategic Moves Mar 28, 2025